FFM
Fairmount Funds Management Portfolio holdings
AUM
$772M
This Quarter Return
-5.26%
1 Year Return
+35.05%
3 Year Return
+1,168.51%
5 Year Return
+1,432.11%
10 Year Return
–
AUM
$437M
AUM Growth
+$437M
(+3.3%)
Cap. Flow
+$75.9M
Cap. Flow
% of AUM
17.37%
Top 10 Holdings %
Top 10 Hldgs %
66.91%
Holding
28
New
6
Increased
6
Reduced
6
Closed
1
Top Buys
| 1 |
BioCryst Pharmaceuticals
BCRX
|
$35.4M |
| 2 |
Neurocrine Biosciences
NBIX
|
$27.6M |
| 3 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$18M |
| 4 |
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
|
$13.4M |
| 5 |
DBVT
DBV Technologies
DBVT
|
$12.3M |
Top Sells
| 1 |
argenx
ARGX
|
$19.2M |
| 2 |
Protagonist Therapeutics
PTGX
|
$13M |
| 3 |
Insmed
INSM
|
$12.3M |
| 4 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$7.31M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
$5.71M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BHVN
1
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $38.5M | 8.81% |
264,206
+24,892
| +10% | +$3.63M |
|
2
Axsome Therapeutics
AXSM
$6.05B
| $36.1M | 8.26% |
942,571
| – | – |
|
|
3
BioCryst Pharmaceuticals
BCRX
$1.74B
| $35.4M | 8.1% |
+3,343,107
| New | +$35.4M |
|
|
GBT
4
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $30.5M | 6.97% |
953,396
-228,911
| -19% | -$7.31M |
|
|
5
argenx
ARGX
$43.6B
| $27.9M | 6.38% |
73,526
-50,718
| -41% | -$19.2M |
|
|
6
Neurocrine Biosciences
NBIX
$13.8B
| $27.6M | 6.31% |
+283,000
| New | +$27.6M |
|
|
7
Insmed
INSM
$28.8B
| $26.2M | 5.99% |
1,326,368
-622,416
| -32% | -$12.3M |
|
8
Cogent Biosciences
COGT
$1.69B
| $24.9M | 5.7% |
2,758,975
+1,200,000
| +77% | +$10.8M |
|
9
Nuvalent
NUVL
$5.52B
| $23.3M | 5.32% |
1,715,518
+377,125
| +28% | +$5.11M |
|
10
Enanta Pharmaceuticals
ENTA
$180M
| $22.2M | 5.08% |
469,264
| – | – |
|
|
ONC
11
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $18M | 4.13% |
+111,400
| New | +$18M |
|
|
CTIC
12
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $13.4M | 3.07% |
+2,245,891
| New | +$13.4M |
|
|
PNT
13
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $12.5M | 2.86% |
1,833,950
-478,573
| -21% | -$3.26M |
|
|
DBVT
14
DBV Technologies
DBVT
$264M
| $12.3M | 2.82% |
+4,831,155
| New | +$12.3M |
|
15
Viridian Therapeutics
VRDN
$1.5B
| $10.9M | 2.5% |
944,092
| – | – |
|
16
Annexon
ANNX
$226M
| $10.9M | 2.5% |
2,892,600
+1,643,457
| +132% | +$6.2M |
|
17
Olema Pharmaceuticals
OLMA
$375M
| $10.9M | 2.49% |
2,669,300
| – | – |
|
|
18
Acadia Pharmaceuticals
ACAD
$4.38B
| $10.6M | 2.42% |
751,804
-405,013
| -35% | -$5.71M |
|
19
Tyra Biosciences
TYRA
$675M
| $10.1M | 2.32% |
1,416,998
+132,008
| +10% | +$944K |
|
|
AMRN
20
Amarin Corp
AMRN
$311M
| $8.32M | 1.9% |
5,584,837
+1,451,600
| +35% | +$2.16M |
|
21
Keros Therapeutics
KROS
$618M
| $7.53M | 1.72% |
272,498
-124,413
| -31% | -$3.44M |
|
22
Trevi Therapeutics
TRVI
$883M
| $4.57M | 1.04% |
+1,624,389
| New | +$4.56M |
|
23
Iovance Biotherapeutics
IOVA
$807M
| $4.3M | 0.98% |
389,588
| – | – |
|
|
VRNA
24
Verona Pharma
VRNA
$9.16B
| $3.88M | 0.89% |
926,602
| – | – |
|
25
Instil Bio
TIL
$182M
| $3.11M | 0.71% |
673,905
| – | – |
|